Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • Jun 15, 2020
    - FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning
    - Now for children (ages 4 and older) and adults with diabetes, this latest technology is the first and only iCGM that sustains performance for up to 14 days, providing trends, insights and actionable data
    - FreeStyle Libre 2 system includes a self-applied sensor (the size of two-stacked quarters) that is easiest glucose sensor to apply[1] and worn on the back of the upper arm, eliminating the need for painful fingersticks to test glucose levels[2]
    - FreeStyle Libre portfolio has been extensively studied with the most real-world users, delivering proven health outcomes[3]
    - FreeStyle Libre 2 system offers enhanced features at the same affordable price as FreeStyle Libre 14 day system, which is a third of the cost of other CGMs[4]
  • Jun 13, 2020
    - Real-world data(1) presented at the American Diabetes Association 80th Scientific Sessions suggest people with type 2 diabetes can achieve similar outcomes to adding insulin therapy for both long-acting insulin or non-insulin users
    - A separate late-breaking trial(2) demonstrates FreeStyle Libre portfolio use is associated with significant reductions of acute diabetes events and hospitalizations for a similar population
  • May 21, 2020
    - Urgent care clinic study shows ID NOW test performance of ≥94.7% positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) compared to lab-based PCR reference tests
    - The Everett Clinic study shows 91.3% positive agreement and 100% negative agreement
    - Ongoing study of hospitalized and nursing home patients tested with late symptom onset shows ≥83.3% positive agreement and ≥96.5% negative agreement
    - Abbott's studies suggest ID NOW performs best in patients tested earlier post symptom onset
    - ID NOW delivers results in minutes rather than days and is helping reduce the spread of infection by detecting more positive patients faster than would otherwise be the case
  • May 21, 2020
    - Abbott's antibody test to be deployed as part of the UK Secretary of State for Health's initiative for highly-reliable, large-scale antibody testing
    - European-made blood test will run on Abbott's ARCHITECT® i1000SR and i2000SR, as well as its Alinity™ i laboratory instruments
    - 800,000 Abbott tests have already been delivered to NHS laboratories across the UK
    - Test demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started
  • May 12, 2020
    - Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March
    - The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours
    - Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization
    - This is Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
  • May 11, 2020
    - Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began
    - Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million in June
    - Abbott expects to submit for CE Mark for its Alinity i SARS-CoV-2 IgG test this week and will initiate global shipments immediately
    - This is Abbott's fourth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
  • May 8, 2020
    - Researchers found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began
    - More than 10 million ARCHITECT antibody tests already have been shipped to hospitals and labs around the world
  • Apr 27, 2020
    -- New authorization from Health Canada allows FreeStyle Libre system to be used by frontline healthcare workers in hospitals to remotely monitor patients' glucose status to minimize exposure during COVID-19 and preserve use of personal protective equipment (PPE)
    -- Abbott will donate 3,000 FreeStyle Libre sensors to Canadian hospitals in need to help accelerate access to technology
  • Apr 16, 2020
    - First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent
    - Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?